Apatinib is a novel antiangiogenic agent specifically targeting VEGFR2.[12] This small molecule tyrosine kinase inhibitor was approved for the second-line treatment of advanced gastric cancer in the People's Republic of China in 2014.[13] It has been currently used in the treatment of a variety of solid tumors, such as advanced gastric cancer, breast cancer, hepatocellular carcinoma, and nonsmall cell lung cancer.[13] In this report, we presented a case with relapsed SCLC who unexpectedly responded to apatinib treatment. Here, KDR is linked to gastric cancer.